A Unique Approach to HIV/AIDS Prevention and Therapy

GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical stage biotechnology company focused on developing and commercializing human vaccines for HIV/AIDS and other infectious agents. GeoVax’s unique vaccine technology is designed for use in uninfected people to protect them from infection should they be exposed to the HIV-1 virus. GeoVax’s 1st generation preventive vaccine recently completed a Phase 2a safety trial through the NIH-sponsored HIV Vaccine Trials Network (HVTN). The vaccine may also prove effective as a treatment to reduce the need for drugs in people already infected with HIV. In December 2012, the Company completed enrollment in a Phase 1 trial conducted at three sites in the United States to test the vaccine’s safety and immunogenicity.

GeoVax HIV/AIDS Vaccine

- **Primary Target:** Vaccinate uninfected humans in order to prevent infection.
  - Phase 2a safety preventive trial completed (1st Gen)
  - Phase 2 planning (2nd Gen) underway
- **Primary Target:** Vaccinate HIV-infected humans to reduce need for drugs.
  - Phase 1 therapeutic human clinical trial underway
- **Properties:** DNA and MVA vaccines express non-infectious virus-like particles to stimulate protective anti-HIV-1 antibodies and T cells (white blood cells).
- **Applications:** Preventive and therapeutic treatment for HIV/AIDS.

Strong Patent Position

GeoVax is the exclusive, worldwide licensee of 39 patents issued or filed on various components and compositions of AIDS vaccine. These are owned or licensed by Emory University.

- 5 issued US patents and 2 US filed patent applications related to MVA vector vaccine technology.
- 1 issued US patent and 3 US filed patent applications covering the DNA vector vaccine.
- Additional 28 issued or filed patents in other major world markets.

GeoVax also has full license rights to 5 issued patents controlling AIDS vaccine manufacturing process.

Scientific Leadership

Dr. Harriet Robinson, Chief Scientific Officer, is a pioneer in DNA vaccines and a leading researcher in HIV/AIDS vaccines. A co-founder of GeoVax, she previously served as Chief of Microbiology and Immunology for the Yerkes National Primate Center of Emory University.

Investment Highlights

- **Collaboration with Leading Institutions:** GeoVax’s technology is exclusively licensed from Emory University and is the result of collaborative research conducted at Emory, the National Institutes of Health (NIH), and the Centers for Disease Control (CDC).
- **Government Support - Resources:** GeoVax’s Phase 1 and 2 safety human clinical trials are conducted by the HVTN, funded by the U.S. National Institutes of Health (NIH).
- **Government Support - Funding:** In addition to clinical trial support, GeoVax has received over $22M in research grants from the NIH in support of the Company’s HIV/AIDS vaccine development efforts.

HIV/AIDS Facts

Statistics directly impacting future market for GeoVax HIV/AIDS vaccine

- 34 M People Living with HIV/AIDS
- 1.7 M Total Deaths Worldwide
- 1.0 M Living with HIV/AIDS in the US
- 16,000 Deaths in the US Alone
- 2.5 M New HIV Infections
- Nearly 7,000 New HIV Infections Daily
Vaccine Technology

GeoVax’s unique two-component vaccine combines DNA priming with live vector boosting (MVA) to elicit high levels of cytolytic T cells (a type of white blood cell) and blocking antibodies. Both the DNA prime and MVA boost express the three major proteins of the HIV-1 virus and produce non-infectious HIV-like particles. This multi-protein approach optimizes protection and limits escape by eliciting protective binding antibody to the natural form of the HIV envelope and broad multi-target cytolytic T cell response. The vaccine has demonstrated excellent safety in over 300 inoculated humans.

The vaccine is the result of a multiyear collaboration between researchers at the Emory Vaccine Center, the NIH, and the CDC. This collaboration has developed an AIDS vaccine for subtype B, which is most common in North America, the European Community, Japan, and Australia. Vaccines for HIV-1 subtypes in other regions of the world are under development and will build on the success of the subtype B vaccine.

Preventive Vaccine

After promising data were obtained in preclinical prevention trials conducted at Emory’s Yerkes Primate Center between 1998 and 2002, GeoVax’s vaccine technology began human testing in Phase 1 clinical trials funded and managed by the NIH-sponsored HVTN. On the basis of the safety and immune response data in these trials, the HVTN recently completed a Phase 2 safety trial for the vaccine. During the past 20 years the HVTN has sponsored over 90 Phase 1 trials for the initial evaluation of safety and immunogenicity of HIV/AIDS vaccines. GeoVax’s vaccine is only the fifth of these vaccines to merit moving to an HVTN Phase 2 trial.

The HIV Vaccine Trials Network has also agreed to sponsor and conduct clinical testing in humans of our second generation preventive vaccine that induced a 90% per exposure reduction of infection by a series of 12 rectal exposures in non-human primates. This vaccine co-expresses granulocyte-macrophage colony-stimulating factor (GM-CSF), a normal human protein that enhances the immune response. Recruitment for the initial Phase 1 trial completed in December 2012.SEP

Therapeutic Vaccine

Highly promising data obtained at the Yerkes National Primate Center have demonstrated the ability of prototypes of the GeoVax vaccine to control infections in already infected non-human primates. In these vaccine trials, primates were infected, placed on oral medication, vaccinated, then taken off drugs to determine the ability of the vaccine to control the infection in the absence of continuing drug treatment. On the basis of these encouraging results, human trials testing the ability of the GeoVax vaccine to act as a therapy are underway with Phase 1 trial enrollment currently in process. This trial is being conducted in individuals who were placed on antiretroviral therapy within their first 18 months of infection. An additional trial is currently being planned. This Phase 1 trial will investigate the safety and immunogenicity of the vaccine used in combination with the standard of care oral medication.

GeoVax Labs, Inc. • 1900 Lake Park Drive, Suite 380 • Atlanta, Georgia 30080 USA
phone: (678) 384-7220 • fax: (678) 384-7283 • investor@geovax.com • www.geovax.com

The information in the fact sheet may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company’s current expectations regarding future events, including the ongoing development of GeoVax vaccine and possible future benefits to the Company, the shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.